Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08JWJ
|
||||
| Former ID |
DCL000593
|
||||
| Drug Name |
PF-1228305
|
||||
| Synonyms |
Thelin; Sitaxentan sodium; Sitaxsentan sodium
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Pulmonary hypertension [ICD9: 416; ICD10:I27.0, I27.2] | Phase 3 | [1] | ||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H14ClN2NaO6S2
|
||||
| Canonical SMILES |
CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)[N-]C4=C(C(=NO4<br />)C)Cl)OCO2.[Na+]
|
||||
| InChI |
1S/C18H14ClN2O6S2.Na/c1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18;/h3-5,7H,6,8H2,1-2H3;/q-1;+1
|
||||
| InChIKey |
MDTNUYUCUYPIHE-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 210421-64-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
12015041, 15318680, 16577869, 23613118, 43529705, 50386535, 50386536, 57376728, 135110232, 152159714, 152258321, 160647160, 160692699, 163124765, 164117708, 164233699, 174528310, 179322759, 185971399, 196108027, 198980810, 204360314, 215771094, 225848332, 241051997, 249828035, 252057354, 252110245, 252451460
|
||||
| SuperDrug ATC ID |
C02KX03
|
||||
| Target and Pathway | |||||
| Target(s) | Endothelin-1 receptor | Target Info | Antagonist | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Renin secretion | |||||
| Pathways in cancer | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PANTHER Pathway | Endothelin signaling pathway | ||||
| Pathway Interaction Database | Endothelins | ||||
| EGFR-dependent Endothelin signaling events | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Pfizer. Product Development Pipeline. March 31 2009. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.